Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment PharmaTimesStudy expands development of the antibody into hepatocellular carcinomaClinical DataOncologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Study expands development of the antibody into hepatocellular carcinoma Clinical DataOncologyRead full story Post navigation Previous: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to EuropeNext: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
